Pradaxa, illustration of capsule form (not a photo of the actual pack)

Illustrative image.

Pradaxa

Dabigatran Etexilate

Prescription required

$147.00

110mg · 3 × 60 capsules · 6 months supply

BrandBranded medicine· By Boehringer

$24.50 per month

Strength

How long a supply?

6 months$24.50 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$294a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

75mg

110mg

150mg

FDA boxed warning(a) premature discontinuation of pradaxa increases the risk of thrombotic events, and (b) spinal/epidural hematoma

(A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including PRADAXA, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy.

(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with PRADAXA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated.

Read this with the rest of the clinical information

About Pradaxa

Overview

Pradaxa contains dabigatran etexilate, an anticoagulant that helps prevent blood clots. In adults, it is used to reduce the risk of stroke and clots travelling through the bloodstream in non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism after initial treatment with an injected anticoagulant, reduce their recurrence, and prevent them after hip replacement surgery. In children aged 8 to under 18, it is used to treat blood clots in the veins after initial treatment with an injected anticoagulant and to reduce their recurrence after previous treatment. It works by blocking thrombin, a substance involved in forming blood clots.

What it treats

• To reduce the risk of stroke and blood clots elsewhere in the body in adults with non-valvular atrial fibrillation. • To treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults after 5–10 days of treatment with an injected anticoagulant. • To reduce the risk of DVT and PE returning in adults who have previously been treated. • To prevent DVT and PE in adults after hip replacement surgery. • To treat venous thromboembolism (VTE) in children aged 8 to under 18 after at least 5 days of treatment with an injected anticoagulant. • To reduce the risk of VTE returning in children aged 8 to under 18 who have previously been treated.

Safety information

Side effects

Common side effects include bleeding and stomach or intestinal problems. Pradaxa can also cause serious or fatal bleeding. Seek urgent medical attention for serious bleeding. Stopping Pradaxa prematurely increases the risk of blood clots; contact your prescriber before stopping treatment. Other serious risks include bleeding around the spine during spinal or epidural procedures, and blood clots or bleeding in people with prosthetic heart valves. Pradaxa is not recommended for people with bioprosthetic heart valves or triple-positive antiphospholipid syndrome, which is associated with an increased risk of blood clots.

FDA boxed warning

(a) premature discontinuation of pradaxa increases the risk of thrombotic events, and (b) spinal/epidural hematoma

(A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including PRADAXA, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy.

(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with PRADAXA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek immediate medical attention for serious bleeding. - Seek immediate medical attention for new problems with movement or sensation after spinal or epidural anesthesia or a spinal puncture. Bleeding around the spine can cause lasting paralysis.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Pradaxa if you have active abnormal bleeding, a mechanical artificial heart valve, or a history of a serious allergic reaction to dabigatran, dabigatran etexilate or any ingredient in the medicine. Pradaxa is not recommended for people with a bioprosthetic heart valve or triple-positive antiphospholipid syndrome. Pradaxa can cause serious or fatal bleeding. The risk of bleeding increases with age. Breastfeeding is not recommended while taking Pradaxa.

Interactions

Tell your doctor if you take medicines known as P-gp inducers or P-gp inhibitors. P-gp inducers should not be taken with Pradaxa. In adults with moderately reduced kidney function, P-gp inhibitors may require the prescriber to adjust treatment or avoid the combination. P-gp inhibitors are not recommended with Pradaxa in adults with severely reduced kidney function.

Using Pradaxa

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label PRADAXA (DABIGATRAN ETEXILATE MESYLATE) CAPSULE [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.] (DailyMed, retrieved 19 September 2026).

Patient information and references

Official and supporting information to read alongside advice from your prescriber or pharmacist.

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines